Top factors impeding access of orphan drugs to patients – so what is being done about them?

In Europe, reimbursement approval vary on a country to country basis, conversely to the centralised regulatory approval landscape that faces all drug developers. It can be argued orphan drug developers face an even greater hurdle with  premium prices that National Health Systems are all too weary of in a global economic crisis. I posed some questions to Carlo Incerti, who …